ARGENX SE business relationships
Companies named in ARGENX SE’s 20-F filed 2026-03-19, and public companies whose annual reports name ARGENX SE. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in ARGENX SE’s annual report 5
“In February 2019, the Company entered into a global collaboration and license agreement with Halozyme Therapeutics,” SEC filing
“In March 2019, the Company entered into a license agreement with AgomAb Therapeutics NV for the” SEC filing
“entered into an exclusive out-license agreement with Zai Lab ( Zai Lab Agreement ), a commercial-stage” SEC filing
“regulations may adversely impact our collaboration with Zai Lab in Mainland China, Hong Kong, Taiwan and Macau” SEC filing
“Collaboration revenue - AbbVie” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.